10 Aug 2022 , 02:29 PM
Net profit of Zydus Lifesciences declined 11.73% to Rs 518.30 crore in the quarter ended June 2022 as against Rs 587.20 crore during the previous quarter ended June 2021. Sales rose 0.14% to Rs 3922.90 crore in the quarter ended June 2022 as against Rs 3917.40 crore during the previous quarter ended June 2021.
| Particulars | Quarter Ended | ||
| ? | Jun. 2022 | Jun. 2021 | % Var. |
| Sales | 3922.90 | 3917.40 | 0 |
| OPM % | 21.02 | 23.82 | – |
| PBDT | 856.30 | 959.70 | -11 |
| PBT | 675.60 | 777.00 | -13 |
| NP | 518.30 | 587.20 | -12 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
